Parkinson’s disease is a most commonly diagnosed age related neurodegenerative disorder, which affects the normal movements of body due to genetic and environmental factors.
Global Parkinson Disease Drug Biomarkers Insight 2028 Report Highlights:
- Global Parkinson’s Disease Antibodies Market Opportunity: > USD 8 Billion
- Parkinson’s Disease Clinical Trials Insight: > 300 Drugs In Trials
- Parkinson’s Disease Biomarkers Sourced During Clinical Trials
- Parkinson’s Disease Insight By Classification
- Insight On Biomarkers Sourced From Trials By Drugs & Indication
- Biomarker Name & Function Insight By Drug
- Biomarker Insight Based On Drugs In Multiple Trials Phase & Multiple Indication
Download Report Sample:
http://biomarkersinsights.com/parkinson-disease-biomarkers-and-clinical-trials-insight-2028
Parkinson’s disease is a most commonly diagnosed age related neurodegenerative disorder, which affects the normal movements of body due to genetic and environmental factors. The traditionally available diagnostic methods have several limitations and they are not available to diagnose Parkinson’s disease in the early stage when treatments are more likely to be effective. Further, recent studies have demonstrated that more than 20% of the time patients are given the wrong diagnosis. Owing to these challenges in the diagnosis of Parkinson disease, there is critical need for the robust biomarkers with the ability to confirm diagnosis in the early stages of disease. Such biomarkers are needed as well to optimize the development of drugs targeting these early stages. Furthermore, a validated biological marker that reflects PD severity/progression is also urgently required.
Biomarkers are naturally occurring biological molecules, which is used as an indicator of biological process, diagnosis, prognosis, pharmacological response to medical intervention and pathophysiology of disease. Biomarkers play a very important role in drug discovery and development since they are helpful in determining the precision of the medicine. High attrition rate of drug development procedure can be improved by using biomarkers in predictive evaluation of drug action in clinical trials. In 2004, the U.S. FDA introduced the Critical Path Initiative to help manufacturers modernize drug development process by incorporating biomarkers in prediction of effectiveness, evaluation of drug safety and effectiveness and mechanism of drug action. Since biomarkers are of utmost importance in drug development, the rapidly expanding pharmaceutical industry will positively impact the growth of Parkinson drug biomarker market.
Recently, research studies have identified α-synuclein which is coded by SNCA gene. Study have revealed that amount of α-synuclein contained within brain-derived exosomes in the blood can provide a biomarker of early-stage Parkinson disease (PD). Owing to this, Amprion has launched its SYNTap Test which uses cerebrospinal fluid (CSF) samples to track misfolded Synuclein, the biomarker driving certain brain diseases including Parkinson disease. The SYNTap Test was designated a breakthrough device by the U.S. Food and Drug Administration to help diagnose people undergoing evaluation for Parkinson’s. The designation is given to products that effectively help identify life-threatening or debilitating diseases for which no alternatives exist or that provide significant advantages over current options.
The key players of this industry are focusing on forming strategic collaborations, acquiring businesses beneficial for their growth to improve their market presence and generate new revenue streams.
As per our report findings, the global Parkinson disease market is expected to surpass US$ 8 Billion by 2028. This is mainly attributed to the rising geriatric population which is associated with the onset of Parkinson disease. The increasing adoption of minimally invasive procedures and personalized medicines are acting as another major growth-inducing factor. Further, advances in genomics and proteomics in combination with bioinformatics have accelerated the development of specific biomarkers for Parkinson disease. In addition, he global Parkinson drug biomarker market is highly competitive in nature with presence of large number of pharmaceutical giants. The key players of this industry are focusing on forming strategic collaborations, acquiring businesses beneficial for their growth to improve their market presence and generate new revenue streams.
This report on global Parkinson disease biomarkers market report provides holistic understanding of the market along with market sizing, forecast, drivers, challenges, and competitive landscape. Our report provides comprehensive analysis on the approved biomarkers for Parkinson disease drugs. Apart from this, in-depth analysis on the ongoing clinical trials in biomarkers associated with novel targeted drugs in development by various phases is also mentioned in the report. The major companies mentioned in the report are Amgen, Roche, Pfizer, Gilead Sciences, GlaxoSmthKline, and others.
Contact:
Sussan
Research Partner
Biomarkers Insights
sample@biomarkersinsights.com